证券代码：300078 证券简称：思创医惠 公告编号：2025-093 思创医惠科技股份有限公司 的收益进行再投资的相关金额）不应超过投资额度。在上述额度内，资金可以循 环滚动使用。 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好、风险较低的投资产品。 2、投资金额：拟使用总额不超过 80,000 万元人民币（含本数）的闲置自有 资金进行现金管理。 3、特别风险提示：受政策风险、信用风险、流动性风险等因素影响，投资 收益具有不确定性，敬请广大投资者注意投资风险。 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开 第六届董事会第十次会议，审议通过了《关于使用部分闲置自有资金进行现金管 理的议案》，同意公司及子公司在确保不影响正常经营和资金安全的情况下，使 用额度合计不超过 80,000 万元人民币（含本数）的闲置自有资金进行现金管理， 用于择机购买安全性高、流动性好、风险较低的投资产品，使用期限自股东会审 议通过之日起 12 个月内有效 ...

非经营性资金占用及其他关联资金往来情况汇总表 2025年半年度 | 编制单位：思创医惠科技股份有限公司 | | | | | | | | | | 单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 关联关系 | 上市公司核算的会 计科目 | 2025年期初 占用资金余额 | 2025年半年度占用 累计发生金额 （不含利息） | 2025年半年度占 用资金的利息 （如有） | 2025年半年度 偿还累计发生 金额 | 2025年6月期末 占用资金余额 | 占用形成原因 | 占用性质 | | 控股股东、实际控制人及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | | | 前控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | - | - | ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-096 思创医惠科技股份有限公司 关于修订、制定及废止公司部分治理制度的公告 其中序号 1 至 7 对应制度尚需提请公司 2025 年第四次临时股东会审议通过 后方能生效；序号 8 至 12 对应制度经公司董事会审议通过后即生效；序号 13 至 15 对应制度经公司董事会审议通过后即废止。修订后的治理制度详见公司于 同日披露于巨潮资讯网（www.cninfo.com.cn）的制度全文，敬请广大投资者查 阅。 特此公告。 思创医惠科技股份有限公司董事会 2025 年 8 月 23 日 思创医惠科技股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开 第六届董事会第十次会议，审议通过了《关于修订、制定及废止公司部分治理制 度的议案》，现将相关情况公告如下： 一、本次修订、制定及废止部分治理制度的原因及依据 为进一步完善公司法人治理结构，优化内控制度体系，提高公司规范运作水 平，公司根据中国证券监督管理委员会和深圳证券交易所最新发布的相关法律、 法规、规范性文件以及公司于近期修订完成的最新《公司章程》，对公司部分治 理制度进行了系统性 ...

思创医惠科技股份有限公司 2025 年半年度报告全文 思创医惠科技股份有限公司 2025 年半年度报告 2025-090 2025 年 8 月 1 思创医惠科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、董事、高级管理人员保证半年度报告内容的真实、准确、 完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 公司负责人许益冉、主管会计工作负责人钱本成及会计机构负责人(会计 主管人员)李秀云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告如有涉及未来计划等前瞻性陈述，均不构成公司对任何投 资者及相关人士的实质承诺，投资者及相关人士均应当对此保持足够的风险 认识，并且应当理解计划、预测与承诺之间的差异，敬请投资者注意投资风 险。 公司在经营管理中可能面临的主要风险与相应举措已在本报告第三节 "管理层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述。 敬请广大投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 02 ...

Core Insights - The stock price of Sichuang Medical has plummeted due to a criminal investigation initiated by the Hangzhou Public Security Bureau regarding fraudulent securities issuance, marking another significant crisis for the company after a hefty fine of 85.7 million yuan imposed by the Zhejiang Securities Regulatory Bureau last year [1][2]. Financial Fraud - Regulatory investigations have uncovered a chain of fraud involving Sichuang Medical, where in 2020, the company inflated profits by 83.94 million yuan, accounting for 67% of the total profit for that period, through its wholly-owned subsidiary, Yihui Technology [2]. Business Impact - The repercussions of the fraud have severely affected the core business of Yihui Technology, which has faced repeated failures in public hospital tenders due to reputational damage. The company's revenue is projected to drop to 169 million yuan in 2024, with a net loss of 320 million yuan, representing a nearly 60% decline from 417 million yuan in 2022 [3]. Strategic Restructuring - On May 30, Sichuang Medical announced the sale of Yihui Technology to a state-owned enterprise for nearly 300 million yuan, marking a complete exit from the smart healthcare sector. The company stated that the divestiture was necessary to concentrate resources on developing business intelligence [4]. Transition Challenges - Following the focus shift to business intelligence, Sichuang Medical aims to leverage its leading global EAS hard tag production capacity and RFID technology. However, the business intelligence segment is expected to see a revenue decline of 15% in 2024, with a gross margin drop of 4.83 percentage points to 21.54%. Despite an increase in revenue share to 72.5%, growth momentum remains insufficient [5].

Core Viewpoint - Sichuang Medical Technology Co., Ltd. is under investigation for suspected fraudulent issuance of securities, with the case currently in the police investigation stage [1] Group 1: Investigation and Legal Issues - The investigation is closely related to previous financial fraud cases, where Sichuang Medical inflated revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflated revenue by 60.96 million yuan and profits by 52.37 million yuan in 2020, accounting for 20.03% and 56.81% of the respective profits [2] - The fraudulent data was included in the annual reports for 2019 and 2020, which were used as important evidence for the issuance of 817 million yuan in convertible bonds in 2021 [3] - The company has faced significant penalties, including a fine of 85.7 million yuan and a 10-year market ban for the former chairman [3] Group 2: Corporate Restructuring - In response to regulatory pressure, the company has made significant adjustments to its ownership structure and business layout, including the resignation of the former chairman and the transfer of control to the Cangnan County Finance Bureau [3] - The company has also divested its subsidiary, Medical Technology Co., which was the main platform for the financial fraud, and has shifted its focus to the Internet of Things sector [4] Group 3: Financial Performance - The company has reported continuous losses, with net profits of -878 million yuan, -874 million yuan, -502 million yuan, and -19.56 million yuan for the years 2022 to 2025 Q1, with a 71.14% reduction in losses for Q1 2025 compared to the same period last year [4] - The company claims that its financial situation has improved since the entry of state-owned capital, with a reduction in losses since 2024 [4] Group 4: Regulatory Environment - The capital market has intensified its crackdown on financial fraud and fraudulent issuance, with a focus on establishing a comprehensive accountability mechanism involving administrative, civil, and criminal responsibilities [5][6] - The ongoing investigation into Sichuang Medical is closely monitored by investors, with the company actively cooperating with the police and preparing compensation plans for affected investors [6]

Core Viewpoint - Sichuang Medical's fraudulent issuance of securities has led to administrative penalties and ongoing criminal investigations, raising concerns about the company's governance and financial stability [1][6][7] Group 1: Fraudulent Issuance and Penalties - Sichuang Medical was penalized by the Zhejiang Securities Regulatory Commission in January 2024 for fraudulent issuance of securities, resulting in fines totaling 85.7 million yuan and a 10-year market ban for the former chairman [4][5] - The fraudulent activities included inflating revenue by 34.93 million yuan and profits by 33.02 million yuan in 2019, and inflating revenue by 96.47 million yuan and profits by 83.94 million yuan in 2020 [3][4] Group 2: Ongoing Investigations - The Hangzhou Public Security Bureau has initiated a criminal investigation into the fraudulent issuance case, indicating potential criminal charges against responsible individuals [6][7] - The company has stated that the investigation is still in progress and does not currently have a significant impact on its operations [2][6] Group 3: Corporate Governance Changes - Following the fraud case, Sichuang Medical underwent significant governance changes, including the exit of key personnel and the entry of state-owned investors, which has led to a more stable operational environment [2][5] - The company reported a decline in revenue from 11.16 billion yuan in 2021 to 6.91 billion yuan in 2024, with net losses persisting over the years [4][5] Group 4: Market Reactions - The news of the criminal investigation led to a 10.08% drop in Sichuang Medical's stock price on August 18 [6][7] - The resignation of the vice president due to personal reasons amid the ongoing investigation has raised further speculation in the market [7]

Market Overview - On August 19, the AI medical sector experienced a slight decline of 0.11%, with Yaobai Technology leading the drop [1] - The Shanghai Composite Index closed at 3727.29, down 0.02%, while the Shenzhen Component Index closed at 11821.63, down 0.12% [1] Stock Performance - Key stocks in the AI medical sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 5.12% to a closing price of 31.40, with a trading volume of 616,700 shares and a transaction value of 1.977 billion [1] - Anbiping (688393) increased by 2.80% to 31.62, with a trading volume of 47,200 shares and a transaction value of 149 million [1] - Yaobai Technology (300725) fell by 3.43% to 48.21, with a trading volume of 196,500 shares and a transaction value of 965 million [2] Capital Flow - The AI medical sector saw a net inflow of 206 million from institutional investors, while retail investors contributed a net inflow of 44.13 million [2] - However, speculative funds experienced a net outflow of 250 million [2] Individual Stock Capital Flow - Seli Medical had a significant net inflow of 356 million from institutional investors, representing 17.99% of its total trading volume [3] - Meinian Health (002044) also saw a net inflow of 121 million from institutional investors, accounting for 12.18% [3] - In contrast, Yaobai Technology experienced a net outflow of 244 million from speculative funds, indicating a negative sentiment [3]

Policy Developments - The National Medical Insurance Administration held a mid-year meeting in Xi'an, focusing on enhancing the development of medical institutions and the pharmaceutical industry, ensuring public health, and improving the basic medical insurance system [2] Drug and Device Approvals - Heng Rui Medicine's application for the marketing license of Haequibopamine tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [4] - Dongfang Bio and its subsidiaries have obtained multiple medical device registration certificates, including flu virus antigen test kits and other diagnostic tools, enhancing the company's product range and market competitiveness [5] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic [6] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [8] - Jiuyuan Gene achieved total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, with over 10% growth in orthopedic product sales despite industry challenges [9] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [11] Capital Market - Kening Bio completed a multi-million A-round financing to support clinical research for its core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [13] Industry Events - A new decision-making framework called FRAME was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights using large language models [15] - Ant Group launched initiatives to combat fake medical advertisements through its AI health application, aiming to protect public interests amid increasing regulatory scrutiny [16] Shareholder Actions - Guoshou Chengda has reduced its stake in Maipu Medical by 2.9958%, completing its share reduction plan [18] - Sichuang Medical's vice president resigned for personal career planning reasons, indicating potential changes in company leadership [19]

Policy Developments - The National Medical Insurance Work Mid-Year Symposium was held in Xi'an, Shaanxi, on August 15, 2025, focusing on the progress and future priorities of medical insurance work, emphasizing the need for empowerment of medical institutions and innovation in the pharmaceutical industry [1] Drug and Device Approvals - Heng Rui Medicine announced that its application for the marketing authorization of Haqubopam Ethanolamine Tablets has been accepted by the National Medical Products Administration, aimed at treating chemotherapy-induced thrombocytopenia in adult patients [2] - Dongfang Bio reported that it and its subsidiaries obtained multiple medical device registration certificates, including flu virus antigen test kits and various antibody test kits, enhancing its product range and market competitiveness [3] - Zhifei Biological's clinical trial application for a component DTP vaccine for adolescents and adults has been accepted, with significant market potential as no similar vaccine is currently approved for this demographic in China [4] Financial Reports - Fuyuan Medicine reported a 1.30% decrease in revenue to 1.634 billion yuan and a 7.83% decline in net profit to 268 million yuan for the first half of 2025 [5] - Jiuyuan Gene announced total revenue of 638.8 million yuan and a net profit of 90.2 million yuan, facing challenges from policy changes and internal adjustments, but showing resilience with over 10% growth in orthopedic product sales [6] - Kangzhe Pharmaceutical reported a 10.8% increase in revenue to approximately 4 billion yuan and a 3.1% rise in net profit to about 930 million yuan for the first half of 2025 [7] Capital Market - Kegong Bio completed a multi-million A-round financing, which will support its clinical research for core pipelines targeting osteoarthritis and dry eye syndrome, with plans to start overseas clinical trials in 2026 [8] Industry Developments - A new decision-making framework for medical large models, FRAME, was proposed by a research team from the Chinese Academy of Sciences, showing significant improvements in medical insights compared to traditional methods [9] - Ant Group has launched initiatives to combat fake medical advertisements through its AI health application, AQ, which includes features for users to verify medical claims [10] Shareholder Actions - Guoshou Chengda has completed a reduction of 2.9958% of its shares in Maipu Medical, reducing its holdings to 1.9093% of the total share capital [11] - Sichuan Medical's Vice President resigned for personal career planning reasons, stepping down from all positions within the company [12]